Latest Headlines

  1. InterVenn Biosciences Announces Clinical Validation Of World’s First Glycoproteomic Diagnostic Test 6/10/2021

    InterVenn Biosciences today announced it has completed clinical and analytical validation in compliance with standards set by the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) of GLORITM, a liquid-biopsy diagnostic test capable of differentiating between malignant and benign female pelvic tumors.

  2. Safeguard DNA Diagnostics Launches Rhinostics Dry Collection Swabs For COVID Testing As Primary Collection Devices For Its Laboratories In The Philippines 6/9/2021

    Safeguard DNA Diagnostics Inc, SDDI, one of the largest chains of infectious disease laboratories in the Philippines, has introduced COVID sample collection using the Rhinostics dry nasal and nasopharyngeal collection swabs.

  3. Castle Biosciences Announces Receipt Of New York Laboratory Permit 6/9/2021

    Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that it has received approval from the New York State Department of Health for its DecisionDx-SCC test

  4. SARS-CoV-2 Antibody Test Developed By Promega Receives CE Mark 6/9/2021

    A SARS-CoV-2 antibody test developed by Promega Corporation, the Lumit Dx SARS-CoV-2 Immunoassay, has received CE marking and is now available in Europe.

  5. Predictive Health Diagnostics Company Announces Strong Momentum With 120,000th PULS Cardiac Test™ Order 6/9/2021

    Predictive Health Diagnostics Company, Inc. ("PHDC" or "the Company"), a diagnostics development platform company that develops, manufactures, and distributes specialty diagnostic tests combining science, technology, and proprietary analytics to detect diseases with significant unmet medical needs, today announced a new milestone with placement of the 120,000th order of the PULS Cardiac Test™, a one-of-a-kind diagnostic blood test that identifies asymptomatic patients at risk of a heart attack who are missed by the current methodologies

  6. Biotech And Pharma Labs Performing Endpoint PCR Can Reduce Amplification Time To 15 Minutes With New Promega Reagent And Eppendorf Instrument Combination 6/8/2021

    Biotech and pharma labs performing endpoint polymerase chain reaction (PCR) can amplify samples in as little as 15 minutes with new Promega GoTaq Rapid Master Mix paired with the Eppendorf Mastercycler X50s thermal cycler.

  7. Foundation Medicine Launches FoundationOne Tracker ctDNA Monitoring Assay For Research Use In Partnership With Natera 6/8/2021

    Foundation Medicine, Inc. and Natera, Inc., today announced the launch of the research use version of FoundationOne Tracker, Foundation Medicine’s personalized circulating tumor DNA (ctDNA) monitoring assay

  8. Precipio Launches HemeScreen® Anemia Panel, A One-Of-Its-Kind Testing Tool 6/8/2021

    Specialty diagnostics company Precipio, Inc.(NASDAQ: PRPO), announced that it has launched the HemeScreen® Anemia Panel as part of its suite of diagnostic tests. The purpose of this panel is to help physicians address one of the more significant clinical challenges they face: anemia of unknown cause.

  9. Differential Ion Mobility Interface Enhances Qualitative And Quantitative Mass Spectral Workflows 6/7/2021

    Scientists in pharmaceutical, biopharmaceutical and clinical research laboratories can benefit from a differential ion mobility interface that increases productivity and data quality for qualitative and quantitative workflows.

  10. Next Generation AutoCapper Takes The Strain Out Of Microplate Sealing 6/7/2021

    Porvair Sciences has announced its next generation AutoCapper electronic sealer - a versatile device designed to take the strain out of applying friction sealing caps to a wide range of microplates